Consensus CONMED Corporation

Stocks

CNMD

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - NYSE Other stock markets 21:00:02 12/06/2026 BST			5-day change	1st Jan Change
34.77 ^USD	+1.05%		-1.11%	-14.36%

06-01	Conmed enters first omnibus amendment and increased facility activation notice on May 27, 2026 - SEC filing	RE
06-01	CONMED Corporation Amends Credit Agreement And Secures USD 450 Million Term Loan Facility	CI

Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

e2705a28b2e8485538b.MuuuK1MVhE-pjDctVqfKDCRCdY03xeMJOKCrWD2w2Gc.Z67UXWR9zCPzzntlYeateRASOdRGoYtsXObKMG2AkF8Er8dJNyP-LeXncg~872548549853e04fca6c6a6a8cb281e7

Analysts' recommendations: CONMED Corporation

05-18	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
03-17	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
12/06/25	Conmed Shares Fall After Needham Downgrade	MT
12/06/25	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
28/04/25	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
06/02/25	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
01/08/24	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
25/07/24	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
25/04/24	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
25/04/24	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
01/02/24	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
01/02/24	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
27/10/23	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
26/10/23	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
27/07/23	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
27/07/23	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
05/06/23	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
22/05/23	CL King Starts CONMED at Buy With $140 Price Target	MT
27/04/23	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
27/04/23	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
27/04/23	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
27/04/23	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT
27/03/23	CONMED Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $124; Firm Sees Financial Profile Improving	MT
27/03/23	Analyst recommendations: Caterpillar, Conmed, Corning, Model N, United Rentals...
03/02/23	Needham Raises Price Target on CONMED to $122 From $106, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
CONMED CORPORATION	-	+13.89%
ABBOTT LABORATORIES		+32.16%
MEDTRONIC PLC		+22.19%
HOYA CORPORATION		+13.98%
CENCORA, INC.		+24.47%
BECTON, DICKINSON AND COMPANY		+23.56%
MEDLINE INC.		+39.31%
DEXCOM, INC.		+12.33%
WEST PHARMACEUTICAL SERVICES, INC.		+9.11%
TERUMO CORPORATION		+34.68%
Average		+22.57%
Weighted average by Cap.		+25.01%